Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Akero Therapeutics. The associated price target remains the same with $84.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors that highlight Akero Therapeutics’ strong position in the market. The recent discontinuation of Novo Nordisk’s zalfermin development, due to lack of efficacy, positions Akero’s efruxifermin (EFX) as a leading candidate in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). EFX is noted for its best-in-class potential, especially in more challenging cases of F2/F3 and F4 MASH.
Furthermore, EFX is the most advanced FGF21 analog currently in development, with ongoing Phase 3 SYNCHRONY trials. Upcoming data readouts from these trials are anticipated to be significant catalysts for Akero, particularly the Real World study data expected in the first half of 2026. These developments, combined with EFX’s promising efficacy and competitive edge, underpin Michael Ulz’s optimistic outlook and Buy rating for Akero Therapeutics.
In another report released on August 4, TD Cowen also initiated coverage with a Buy rating on the stock with a $76.00 price target.